17:32 EST Agile Therapeutics files to sell $15M of common stock, Series E-1 warrants
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGRX:
- Agile Therapeutics reports Q3 EPS ($1.47) vs ($3.10) last year
- Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Is AGRX a Buy, Before Earnings?
- Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023